Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling; $5M total (Two Sigma/NCI SBIR) competing with Foundation Medicine and Tempus AI for comprehensive genomic profiling in pediatric and rare cancers.
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
Autonomous mobile robot company for warehouse automation; flexible AMR-based fulfillment systems that adapt to changing product mixes without fixed infrastructure.
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and manufacturing facilities. The company builds ground-based autonomous robots capable of transporting goods, fulfilling orders, and navigating dynamic warehouse environments alongside human workers, with software for fleet management and warehouse orchestration.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.